The CMA investigated the anticipated acquisition by Vectura Group plc of Skyepharma plc.
|Phase 1 date||Action|
|24 May 2016||Decision published|
|16 May 2016||Decision announced|
|27 April to 12 May 2016||Invitation to comment|
|27 April 2016||Launch of merger inquiry|
FNTQ decision announced
16 May 2016: The CMA has today decided that the anticipated acquisition by Vectura Group plc of Skyepharma plc does not qualify for investigation under the merger provisions of the Enterprise Act 2002. The full text of the decision is available below.
- Full text decision (24.5.16)
Invitation to comment: Now closed
27 April 2016: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
Launch of merger inquiry
27 April 2016: The CMA announced the launch of its merger inquiry by notice to the parties.
- Commencement of initial period notice (27.4.16)
Please send written representations about any competition or public interest to:
Competition and Markets Authority
Published: 27 April 2016
Updated: 24 May 2016
Opened: 27 April 2016
Closed: 24 May 2016
- Full text decision published.
- Found not to qualify decision announced.
- First published.